CEP162

Across TCGA pan-cancer cohorts, CEP162 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CEP162’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where CEP162 RNA is repressed in tumor relative to normal tissue. In most cancer types CEP162 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

KICH, THCA, and LIHC are the cancer types where CEP162 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CEP162 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	Female	All	−1.600	<.001	8	view →
THCA	Male	II,III,IV	−0.827	<.001	8	view →
LIHC	All	II,III,IV	+0.577	<.001	7	view →
HNSC	All	III,IV	+0.493	.004	7	view →
BRCA	Female	All	−0.325	<.001	6	view →
LUAD	Female	II,III,IV	−0.500	.013	5	view →
CHOL	Male	All	+1.843	<.001	4	view →
UCEC	All	IV	−0.990	.014	2	view →
KIRP	All	IV	+0.945	.016	2	view →
PRAD	All	All	−0.376	<.001	2	view →
STAD	Male	II,III,IV	+0.433	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CEP162–KICH

Open the KICH breakdown →